ZA200807630B - Affinity Regions - Google Patents

Affinity Regions

Info

Publication number
ZA200807630B
ZA200807630B ZA200807630A ZA200807630A ZA200807630B ZA 200807630 B ZA200807630 B ZA 200807630B ZA 200807630 A ZA200807630 A ZA 200807630A ZA 200807630 A ZA200807630 A ZA 200807630A ZA 200807630 B ZA200807630 B ZA 200807630B
Authority
ZA
South Africa
Prior art keywords
affinity regions
affinity
regions
Prior art date
Application number
ZA200807630A
Other languages
English (en)
Inventor
Martijn Frans Ben Gerard Gebbink
Barend Baima
Original Assignee
Crossbeta Biosciences Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crossbeta Biosciences Bv filed Critical Crossbeta Biosciences Bv
Publication of ZA200807630B publication Critical patent/ZA200807630B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA200807630A 2006-02-16 2008-09-04 Affinity Regions ZA200807630B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06075355A EP1820806A1 (en) 2006-02-16 2006-02-16 Affinity regions

Publications (1)

Publication Number Publication Date
ZA200807630B true ZA200807630B (en) 2009-12-30

Family

ID=36792791

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200807630A ZA200807630B (en) 2006-02-16 2008-09-04 Affinity Regions

Country Status (9)

Country Link
US (1) US20090155254A1 (cg-RX-API-DMAC7.html)
EP (2) EP1820806A1 (cg-RX-API-DMAC7.html)
JP (1) JP2009529657A (cg-RX-API-DMAC7.html)
CN (1) CN101421304A (cg-RX-API-DMAC7.html)
AU (1) AU2007215621A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0707848A2 (cg-RX-API-DMAC7.html)
CA (1) CA2642828A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007094668A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200807630B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
US20090202980A1 (en) * 2005-03-21 2009-08-13 Crossbeta Biosciences B.V. Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
WO2007008072A2 (en) * 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. CROSS-ß STRUCTURE BINDING COMPOUNDS
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
EP1907864A2 (en) * 2005-07-13 2008-04-09 Crossbeta Biosciences B.V. METHODS FOR DETERMINING THE EFFECT OF A TREATMENT ON THE CROSS-ß STRUCTURE CONTENT OF A PROTEIN; SELECTION OF TREATMENTS AND USES THEREOF
US20100015126A1 (en) * 2006-03-17 2010-01-21 Martijn Frans Ben Gerard Gebbink Methods of Binding of Cross-Beta Structures By Chaperones
JP5229789B2 (ja) * 2007-02-27 2013-07-03 プリマハム株式会社 新規ストレスバイオマーカー及びその用途
EP2058001A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Enhancement of immunogenicity of antigens
EP2058000A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Immunogenic compositions capable of activating T cells
CA2716521A1 (en) 2008-02-29 2009-09-11 Baxter Healthcare S.A. Anti-amyloid .beta. activity of intravenous immunoglobulin (ivig) in vitro
DE102011003944A1 (de) 2011-02-10 2012-08-16 Oxprotect Gmbh Detektion und Entfernung von missgefalteten Proteinen/Peptiden
EP3022225B1 (en) * 2013-07-19 2021-09-29 Board Of Regents Of the University Of Texas System Transthyretin amyloid-selective and polyreactive catabodies
PL3191599T3 (pl) * 2014-09-11 2023-12-27 Board Of Regents Of The University Of Texas System Wykrywanie nieprawidłowo sfałdowanych białek
US20170329892A1 (en) * 2016-05-10 2017-11-16 Accutar Biotechnology Inc. Computational method for classifying and predicting protein side chain conformations
EP3309550A1 (en) * 2016-10-12 2018-04-18 sphingotec GmbH Method for the detection of apolipoprotein e4
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN113390836B (zh) * 2020-03-13 2023-09-29 吉林大学 硫磺素t的应用及一种牛奶中酪蛋白的检测方法
CN114441466B (zh) * 2020-11-04 2025-03-28 厦门红观生物科技有限公司 一种利用ApoJ抑制ApoB100热聚集的方法及定量检测ApoJ活性的方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733524A (en) * 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5801200A (en) * 1984-03-19 1998-09-01 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5700447A (en) * 1992-05-21 1997-12-23 The Picowder Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
US5869534A (en) * 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US5733933A (en) * 1984-03-19 1998-03-31 The Picower Institute For Medical Research Methods and materials for the diagnosis and treatment of conditions such as stroke
EP0319144A1 (en) * 1987-11-06 1989-06-07 Asahi Kasei Kogyo Kabushiki Kaisha Adsorbent of beta 2-microglobulin
EP0321703B1 (en) * 1987-11-20 1993-04-28 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Absorbent for serum amyloid protein
US5216127A (en) * 1987-11-20 1993-06-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Adsorbent for serum amyloid protein
US5180615A (en) * 1989-12-13 1993-01-19 W.R. Grace & Co.-Conn. Metallized bag for static protection of electronic components
US5650418A (en) * 1990-06-04 1997-07-22 Therapy 2000 Therapeutic lysine salt composition and method of use
US5278189A (en) * 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
US5230996A (en) * 1990-06-04 1993-07-27 Therapy 2000 Use of ascorbate and tranexamic acid solution for organ and blood vessel treatment prior to transplantation
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5276059A (en) * 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
US5958883A (en) * 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
US5560418A (en) * 1993-04-02 1996-10-01 Advantage Office Systems, L.L.C. Attachment bar for partition panel
US5449663A (en) * 1993-06-11 1995-09-12 Bicher; Haim I. Antineoplastic compositions
US5935927A (en) * 1994-02-03 1999-08-10 The Picower Institute For Medical Research Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts
US6410598B1 (en) * 1994-02-03 2002-06-25 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US6136548A (en) * 1994-11-22 2000-10-24 Rutgers, The State University Of New Jersey Methods for identifying useful T-PA mutant derivatives for treatment of vascular hemorrhaging
US5854215A (en) * 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
CA2214247C (en) * 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US5817626A (en) * 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5948763A (en) * 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
US6436969B1 (en) * 1995-09-12 2002-08-20 Kansas University Medical Center Research Institute Inc. Dialysis solutions and methods
US5985242A (en) * 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US6310046B1 (en) * 1995-11-17 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Sequestrin of Plasmodium falciparum
WO1997026919A2 (en) * 1996-01-24 1997-07-31 Warner-Lambert Company Method of imaging amyloid deposits
US5785187A (en) * 1996-04-29 1998-07-28 Lipman; Daniel Mechandising display assembly
US6034211A (en) * 1996-06-03 2000-03-07 Kelly; Jeffery W. β-sheet nucleating peptidomimetics
US6929807B1 (en) * 1996-08-09 2005-08-16 Mannatech, Inc. Compositions of plant carbohydrates as dietary supplements
US6372473B1 (en) * 1997-05-28 2002-04-16 Human Genome Sciences, Inc. Tissue plasminogen activator-like protease
EP1014996B1 (en) * 1997-08-28 2003-05-28 University of Washington Saccharide-containing compositions for treating alzheimer's disease and other amyloidoses
CA2306875C (en) * 1997-10-24 2011-01-04 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
WO1999060024A1 (en) * 1998-05-21 1999-11-25 The University Of Tennessee Research Corporation Methods for amyloid removal using anti-amyloid antibodies
JP2001227537A (ja) * 2000-02-18 2001-08-24 Nsk Ltd 直動案内装置
AU783144B2 (en) * 2000-02-21 2005-09-29 H. Lundbeck A/S Novel method for down-regulation of amyloid
HUP0300067A3 (en) * 2000-02-21 2010-03-29 Lundbeck & Co As H Novel method for down-regulation of amyloid
EP1130031A1 (en) * 2000-02-25 2001-09-05 Universitair Medisch Centrum Utrecht Method for inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity
EP1172378A1 (en) * 2000-07-12 2002-01-16 Richard Dr. Dodel Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
EP2264018B1 (en) * 2000-08-24 2015-02-11 University of Pittsburgh - Of the Commonwealth System of Higher Education Thioflavin derivatives for use in the diagnosis of Alzheimer's disease
US7270800B2 (en) * 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
CA2453403C (en) * 2001-07-09 2013-10-08 Elan Pharmaceuticals, Inc. Methods of inhibiting amyloid toxicity
JP2003024080A (ja) * 2001-07-19 2003-01-28 Univ Tokyo ｐ５３依存性アポトーシス誘導タンパク質、およびアポトーシス調節剤のスクリーニング方法
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
US20050142611A1 (en) * 2002-09-30 2005-06-30 Auburn University Method of isolation and self-assembly of small protein particles from blood and other biological materials
EP1907864A2 (en) * 2005-07-13 2008-04-09 Crossbeta Biosciences B.V. METHODS FOR DETERMINING THE EFFECT OF A TREATMENT ON THE CROSS-ß STRUCTURE CONTENT OF A PROTEIN; SELECTION OF TREATMENTS AND USES THEREOF
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
WO2007008072A2 (en) * 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. CROSS-ß STRUCTURE BINDING COMPOUNDS
US20070015133A1 (en) * 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein

Also Published As

Publication number Publication date
CN101421304A (zh) 2009-04-29
BRPI0707848A2 (pt) 2011-05-10
JP2009529657A (ja) 2009-08-20
EP1996620A1 (en) 2008-12-03
WO2007094668A1 (en) 2007-08-23
US20090155254A1 (en) 2009-06-18
AU2007215621A1 (en) 2007-08-23
EP1820806A1 (en) 2007-08-22
CA2642828A1 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
ZA200807630B (en) Affinity Regions
DE602007002700D1 (en) Interventionsfreies frac-system
EP2078282A4 (en) ELECTRONIC COUPONS
DE602007008085D1 (en) Dihydropyrazolopyrimidinonderivate
DE602007014031D1 (en) Luftreifensatz
DE602007002070D1 (en) 2-pyrazincarboxamidderivate
DE602007001601D1 (en) Glasuntersuchung
EP1983992A4 (en) 2-IMINO-BENZIMIDAZOLES
DE602007003855D1 (en) Isothermer reaktor
DE602007006989D1 (en) Spiropiperidinderivate
GB0616770D0 (en) Cardlock
EP2084019A4 (en) PAINT SCRAPER
AP2008004724A0 (en) Substituted1-yl)-azolin-2-aryl-1-hetaryl-ethane
DE602007011622D1 (en) Penem-prodrugs
EP2024567A4 (en) TONTAPETE
EP2007388A4 (en) OPIOPATHIEN
DK1989111T3 (en) Satellitluftbremseapparat
EP1974618A4 (en) UNDERWEAR
DE502007001126D1 (en) Eiten
GB0601584D0 (en) Cosyhold headscarf
AU3514P (en) ARCBENT Arctotis fastuosa
GB0617481D0 (en) Modification
GB0609986D0 (en) Corcost 5e
GB0600579D0 (en) Subtoair
GB0601463D0 (en) Playmat